Efficacy and safety of the biosimilar Infliximab in the patients with ulcerative colitis
Not Applicable
- Conditions
- ulcerative colitis
- Registration Number
- JPRN-UMIN000027465
- Lead Sponsor
- niversity of Toyama
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients younger than 20 years old 2) Patients keeping in the clinical remission state for more than 10 years
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The remission rate and the adverse events 24 and 48 weeks after the switch from infliximab to its biosimilar
- Secondary Outcome Measures
Name Time Method The value of partial Mayo's score The value of serum CRP The value of serum albumin The value of hemoglobin The increase of Infliximab or biosimilar Infliximab